Neoadjuvant chemoradiation therapy followed by the surgical resection of residual disease has become the most common treatment strategy for locally advanced disease despite the lack of a convincing phase III trial supporting this treatment approach. This year’s ASCO meeting saw the presentation of the first results of neoadjuvant chemoradiotherapy replacing old drugs such as Cisplatin by newer substances such as Oxaliplatin, Docetaxel and the integration of biological agents into the preoperative approach.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Leichman L, Goldman BH, Benedetti JK, Billiningsley KG, Thomas CR, Iqbal S, Lenz H, Blanke C, Gold PJ and Corless CL (2009). Oxaliplatin (OXP) plus protraced infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): a southwest oncology group (SWOG) phase Iitrial with molecular correlates (S0356). J Clin Oncol 27: 205s(#4513)
Pasini F, de Manzoni G, Stievano L, Grandinetti A, Maluta S, Capirci C, Durante E, Bonetti A, Zanoni A and Cordiano C (2009). Effect of neoadjuvant combined modality therapy with weekly docetaxel (D) and cisplatin (P), 5-fluorouracil (5-FU) continuous infusion (c.i.), and concurrent radiotherapy (RT) on pathological response rate in esophageal cancers (EC): a phase II study. J Clin Oncol 27: 213s(#4548)
De Vita F., Orditura M, Innocente R, Vecchione L, Pinto C, Chiarion Sileni V, Martinelli E, Ruol A, Catalano G and Ciardiello F (2009). A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC). J Clin Oncol 27: 213s(#4546)
Agarwala AK, Hanna N, Mc Collum A, Bechar N, Di Maio M, Yu M, Tong Y, Becerra CR and Choy H (2009). Preoperative cetuximab and radiation (XRT) fpr patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: a pilot study from the Hoosier Oncology Group and the university of Texas Southwestern. J Clin Oncol 27: 216s(#4557)
Ruhstaller T, Pless M, Schuller JC, Kranzbühler H, Moos R, Moosmann P, Rauch D, Montemurro M, Schneider PM and Hess V (2009). Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective multicenter phase Ib-Iitrial of the Swiss Group for Clinical Cancer Research (SAKK 75/06). J Clin Oncol 27: 219s(#4570)
Ilson D, Bains M, Rizk N, Rusch V, Flores R, Park B, Shah M, Kelsen D, Miron B and Goodman K (2009). Phase Iitrial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin ©, and radiation (RT) in esophageal adenocarcinoma: preliminary safety analysis. J Clin Oncol 27: 220s(#4573)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eisterer, W. Oesophageal cancer – ASCO 2009. memo 2, 221–222 (2009). https://doi.org/10.1007/s12254-009-0167-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-009-0167-x